ESOT Masterclass

From Liquid Biopsy to Tissue Gene Expression: The Impact of New Technologies on Clinical Practice in Solid Organ Transplantation (SOT)

Date: 14 – 15 June, 2024

Location: Mercure Hotel Stare Miasto
Krakow, Poland

Advancements in molecular biology technology allowed the development of promising biomarkers, such as Peripheral blood gene expression profiling (GEP) and cell-free DNA (cfDNA), for minimally invasive diagnosis and characterisation of allograft rejection. The use of circulating GEP and cfDNA may offer advantages over invasive tissue biopsy as a quantitative measure for detection of transplant rejection, immunosuppression optimisation and follow-up after treatment. However, there is no standard recognition of the usage of this new technology.

With the intention of fostering awareness around this topic, during the TLJ 3.0 Consensus conference held in Prague, November 2022, a panel of experts developed guidelines on the use of Molecular Biology testing for Non-Invasive Diagnosis of Allograft Rejection pertaining to the Kidney, Heart & Lung, and Liver. These guidelines were submitted in the form of three papers and have been published on Transplant International.

This masterclass was designed based on the outcomes of these guidelines. It will cover all the cutting-edge technologies that are about to revolutionise the transplantation field, including cell-free DNA, new plasma, urinary and immune function biomarkers, gene-expression profiling, as well as recent advances on HLA and non-HLA antibodies.

Learning Objectives:
After attending this masterclass participants will be able to:
- Gain insight into all the cutting-edge technologies in the transplantation field;
- Learning the ESOT recommendations on testing for non-invasive diagnosis of SOT rejection;
- Put recent discoveries into clinical context.

Target Audience:
Solid Organ Transplant professionals, who are within 5 years of senior appointment.
Professional Background: Nephrology, Cardio Thoracic, Scientist, Allied Health Care Professionals

Grant applications:
This masterclass is open to 25 participants and it is by application only. Registration is provided upon application approval.

Successful candidates will receive a 300 EUR grant covering travel expenses. Accommodation will be provided by the Organisers at the venue of the Masterclass. For more information on how to apply, please visit the website at this link.
Scientific Organisers:
David Cucchiari (Spain)
Dilan Dabare (UK)
Luciano Potena (Italy)

Faculty:
Marta Jimenez Blanco-Bravo (Spain)
David Cucchiari (Spain)
Eric Epailly (France)
Valentin Goutaudier (France)
Delphine Kervella (Spain)
Carmen Lefaucheur (France)
Guido Moll (Germany)
Andriana Nikolova (US)
Bianca de Nicolo (Italy)
Sook Hyeon Park (US)
Luciano Potena (Italy)
Gianluigi Zaza (Italy)

This project is possible thanks to the kind support of CareDX and Eurofins
## Preliminary Scientific Programme – 14 June 2024

### Session 1  Introduction of ESOT Guidelines on Biomarkers (14:30 – 16:00)

**Moderator:** Luciano Potena (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Duration</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Welcome Address</td>
<td>5 min</td>
<td>David Cucchiari (Spain)</td>
</tr>
<tr>
<td>14:35</td>
<td>Overview of Biomarkers in Transplantation: What to expect?</td>
<td>25 min</td>
<td>Carmen Lefaucheur (France)</td>
</tr>
</tbody>
</table>
| 15:00| Guidelines Presentation: **Kidney**  
*European Society of Organ Transplantation Consensus Statement on Testing for Non-Invasive Diagnosis of Kidney Allograft Rejection* | 20 min | Sook Hyeon Park (US) |
| 15:20| Guidelines Presentation: **Heart & Lung**  
*European Society for Organ Transplantation Statement on the use of non-invasive biomarkers for cardiothoracic transplant rejection surveillance* | 20 min | Andriana Nikolova (US) |
| 15:40| Discussion | 20 min | |

**Coffee Break: 16:00 – 16:30**

### Session 2  Donor derived cfDNA (16:30 – 18:00)

**Moderator:** Gianluigi Zaza (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Duration</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>Challenges of setting up of cfDNA assay</td>
<td>25 min</td>
<td>Bianca de Nicolo (Italy)</td>
</tr>
<tr>
<td>16:55</td>
<td>cfDNA in Kidneys &amp; Pancreas</td>
<td>25 min</td>
<td>Louise Benning (Germany)</td>
</tr>
<tr>
<td>17:20</td>
<td>cfDNA in Heart &amp; Lung</td>
<td>25 min</td>
<td>Luciano Potena (Italy)</td>
</tr>
</tbody>
</table>
| 17:45| Panel Discussion | 15 min | **Moderator:** Gianluigi Zaza (Italy)  
**Panellists:** Bianca De Nicolo, Luciano Potena, Louise Benning (Germany) |
Preliminary Scientific Programme – 15 June 2024

Session 3    Other Biomarkers (09:00 – 10:40)

Moderator: Name to be confirmed

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Duration</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Urinary</td>
<td>20 min</td>
<td>Gianluigi Zaza (Italy)</td>
</tr>
<tr>
<td>09:20</td>
<td>Gene expression</td>
<td>20 min</td>
<td>Valentin Goutaudier (France)</td>
</tr>
<tr>
<td>09:40</td>
<td>Cardiac biomarkers</td>
<td>20 min</td>
<td>Marta Jimenez Bravo-Bravo (Spain)</td>
</tr>
<tr>
<td>10:00</td>
<td>Immune function biomarkers</td>
<td>20 min</td>
<td>Delphine Kervella (Spain)</td>
</tr>
<tr>
<td>10:20</td>
<td>HLA and non-HLA donor specific antibodies</td>
<td>20 min</td>
<td>Guido Moll (Germany)</td>
</tr>
</tbody>
</table>

Coffee Break: 10:40 – 11:00

Session 4    Clinical Case Discussion (11:00 – 12:00)

Format: Participants will be divided into two groups. Clinical case studies will be presented and discussed during the parallel sessions.

<table>
<thead>
<tr>
<th>Time</th>
<th>Discussion</th>
<th>Duration</th>
<th>Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Parallel discussion: Kidney</td>
<td>30 min</td>
<td>David Cucchiari (Spain) Louise Benning (Germany)</td>
</tr>
<tr>
<td>11:00</td>
<td>Parallel discussion: Thoracic</td>
<td>30 min</td>
<td>Marta Jimenez Bravo-Bravo (Spain) Luciano Potena (Italy)</td>
</tr>
<tr>
<td>11:30</td>
<td>Biomarker application in clinical practice &amp; what can we expect in the future?</td>
<td>20 min</td>
<td>Luciano Potena (Italy)</td>
</tr>
<tr>
<td>11:50</td>
<td>Closing Remarks</td>
<td>10 min</td>
<td>David Cucchiari (Spain) Luciano Potena (Italy)</td>
</tr>
</tbody>
</table>

This project is possible thanks to the kind support of CareDX and Eurofins